Igmesine

Drug Profile

Igmesine

Alternative Names: CI 1019; JO 1784

Latest Information Update: 24 Jun 2003

Price : $50

At a glance

  • Originator Jouveinal
  • Developer Jouveinal; Pfizer
  • Class Antidepressants; Antidiarrhoeals; Cinnamates; Cyclopropanes; Small molecules
  • Mechanism of Action Opioid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Cognition disorders; Diarrhoea; Major depressive disorder

Most Recent Events

  • 31 Jul 2001 This compound is still in active development
  • 21 Jun 2000 Warner-Lambert has merged with Pfizer
  • 20 Nov 1998 A study has been added to the adverse events section and the Affective disorders therapeutic trials section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top